New biologic combo aims to spare bladders in cancer fight
NCT ID NCT07445308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new biologic drug called SPGL008, given alone or with the standard therapy BCG, in 120 people with high-risk non-muscle-invasive bladder cancer who are not candidates for bladder removal. The main goals are to find a safe dose and see if the drug can control the cancer. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPGL008 (a biologic) alone or combined with BCG
What this could lead to
If successful, this could point toward a new treatment option for people with high-risk bladder cancer who cannot or choose not to have bladder removal surgery.
What could go wrong
This is an early-phase trial with only 120 participants, so it is too soon to know if SPGL008 works. Side effects are possible, and the combination with BCG may increase risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMIBC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••